Navigation Links
YM BIOSCIENCES' NIMOTUZUMAB SELECTED FOR MULTINATIONAL PHASE III TRIAL BY NATIONAL CANCER CENTRE OF SINGAPORE
Date:1/5/2009

    Singapore investigators to coordinate 700 patient trial of EGFR targeting
    antibody for treatment of head and neck cancer

MISSISSAUGA, ON, Jan. 5 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Alternext US:YMI, TSX:YM, AIM:YMBA), an oncology company that identifies, develops and commercializes differentiated products for patients worldwide, today announced that the National Cancer Centre of Singapore (NCCS) has selected nimotuzumab, YM's EGFR-targeting drug, for evaluation in a multinational Phase III trial of more than 700 patients with cancers of the head and neck. The NCCS stated that it selected nimotuzumab because of its reported preferential safety profile compared with other EGFR-targeting cancer drugs. The trial is sponsored by the NCCS in collaboration with Innogene Kalbiotech Pte. Ltd, ("IGK") YM's licensee for nimotuzumab for the region.

"The efficacy of nimotuzumab as an epidermal growth factor receptor targeted therapy is likely to be comparable to drugs of the same class. However, what is likely to set nimotuzumab apart is its low toxicity and favourable safety profile," said Dr. Rikrik Ilyas, Director of IGK. "Patients are spared the discomfort of severe skin rashes and may benefit from an enhanced quality of life. Both patients and physicians may also benefit from lack of hypomagnesemia often related to treatment with other anti-EGFR targeted drugs. IGK is pleased to support the NCCS in this investigator-initiated trial of nimotuzumab."

The NCCS is the lead cancer centre coordinating this clinical trial, which will involve approximately 22 institutions from 12 countries worldwide. The trial will treat patients with locally advanced squamous cell cancers of the head and neck immediately following surgery - the "adjuvant setting". Along with standard chemotherapy and radiotherapy, half of the patients will be administered nimotuzumab weekly for an eight week period. The primary endpoint for th
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
2. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
3. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
6. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
7. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
8. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
9. Pressure BioSciences, Inc. Issued First Patent in Canada
10. Neurocrine Biosciences to Present at the BioCentury: Newsmakers in the Biotech Industry Conference
11. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... Each year in the US, ... attention. In the military, burn injury is a ... medical care. More than 800 service members sustained ... heal slowly, remain inflamed and often become infected, ... and functionally damaging. While developments in supportive care ...
(Date:9/29/2014)... at the forefront of diagnostics today, with imaging ... tomography), scanning, and NMR (nuclear magnetic resonance) increasing ... problems of image resolution and quality still limit ... tissue. A solution is hyperpolarization, which involves injecting ... quality by following the distribution and fate of ...
(Date:9/29/2014)... conflicts in Iraq and Afghanistan, more than 300,000 soldiers ... injury caused by exposure to bomb blasts and ... Symptoms of traumatic brain injury can range from the ... severe impairments in memory and cognition. , Since ... critical importance and complexity of this problem, and has ...
(Date:9/29/2014)... Va. , Sept. 29, 2014  Ten ... the fields of cartilage repair, regeneration, allograft reconstruction ... from around the world gathered to discuss the ... Health Institute of Regenerative Medicine symposium, Cartilage ... . Topics included Orthopedic Biosurgery, Minced Juvenile Allograft, ...
Breaking Biology Technology:Faster Healing with Fewer Scars 2A safer approach for diagnostic medical imaging 2A safer approach for diagnostic medical imaging 3Modeling shockwaves through the brain 2Modeling shockwaves through the brain 3Modeling shockwaves through the brain 4World Renowned Experts Discuss Future Of Cartilage Regeneration 2World Renowned Experts Discuss Future Of Cartilage Regeneration 3
... Dendreon Corporation,(Nasdaq: DNDN ) today announced ... NEUVENGE, an investigational active cellular immunotherapy, in the,August ... The article highlights,the safety profile, immune response and ... cancer who have failed standard,therapy. "In addition ...
... Inc., a biotechnology company developing pharmaceutical products for ... dollar financing deal. The majority of the funding, ... the remainder was borrowed from the Madison Development ... Funds, a private investment firm. The funds raised ...
... more than a marketing campaign and the involvement of ... managers, senior executives and middle managers responsible for creating ... play a vital role in marketing the brand. Employees ... work. , ,Be Your Message. Employer brand building ...
Cached Biology Technology:Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients 2Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients 3Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients 4Quintessence Secures Financing 2Quintessence Secures Financing 3Employer Brands Require More Than Slick Marketing 2
(Date:9/29/2014)... A University of Texas at Arlington research team says ... built in their lab could open doors for homeland ... be published in the Oct. 1 issue of ... and his co-authors describe a new method to fabricate ... and oxygen until a transparent ceramic is formed. ...
(Date:9/29/2014)... has received a five-year, $6 million grant for ... evaluation and development of safe and effective treatments ... from the National Institutes of Health, National Institute ... for Medication Development for Cocaine Use Disorder to ... guide decisions on moving forward with more expensive ...
(Date:9/29/2014)... For decades, planetary geologists have speculated that glaciers ... 2000-mile-long chasm that constitutes the Grand Canyon of ... that might have been carved by past glaciers ... observations have remained highly controversial and contested. ... College and the Freie Universitaet Berlin has identified ...
Breaking Biology News(10 mins):UT Arlington researchers develop new transparent nanoscintillators for radiation detection 2UT Arlington researchers develop new transparent nanoscintillators for radiation detection 3New VCU center to target cocaine addiction 2Glaciers in the Grand Canyon of Mars? 2Glaciers in the Grand Canyon of Mars? 3Glaciers in the Grand Canyon of Mars? 4Glaciers in the Grand Canyon of Mars? 5Glaciers in the Grand Canyon of Mars? 6Glaciers in the Grand Canyon of Mars? 7Glaciers in the Grand Canyon of Mars? 8Glaciers in the Grand Canyon of Mars? 9
... (Santa Barbara, Calif.) An international team of researchers ... that happens in virtually every cell of our bodies. ... folded chains of amino acids assume their specific shapes, ... widely: In the human body, proteins fold to become ...
... family history of liver cancer is reported to increase risk ... findings published in the May issue of Hepatology , ... Liver Diseases. The study also shows 70-fold elevated risk of ... markers for hepatitis B (HBV) or hepatitis C (HCV). ...
... Princeton University researchers have observed a self-degradation response to ... provide new answers to lingering questions among scientists about ... that depression is not solely linked to the neurotransmitter ... PLoS ONE , researchers based in the lab of ...
Cached Biology News:In protein folding, internal friction may play a more significant role than previously thought 2Family history of liver cancer increases risk of developing the disease 2Yeast cell reaction to Zoloft suggests alternative cause, drug target for depression 2Yeast cell reaction to Zoloft suggests alternative cause, drug target for depression 3Yeast cell reaction to Zoloft suggests alternative cause, drug target for depression 4
... xi 2-D system runs both gel dimensions in the ... can be separated in a single run using the ... in much the same manner as the slab gel ... slab gels may be cast in the casting stand. ...
... Application Series are a line of ... provide fast and reliable automated solutions ... robust "automation-friendly" building blocks, Caliper has ... less than conventional approaches, take up ...
... 2-Methyl-3,5,7,8-tetrahydrothiopyrano[4,3-d]pyrimidine-4-one White solid. ... A brain-permeable and water soluble pyrimidinone compound ... + -competitive inhibitor of PARP (IC 50 ... for rhPARP1 and rmPARP2, respectively) with little ...
...
Biology Products: